Author/Authors :
Jarraya, Faical Sfax University Hospital - Department of Nephrology, Tunisia , Mkawar, Khaled Sfax University Hospital - Department of Nephrology, Tunisia , Kammoun, Khawla Sfax University Hospital - Department of Nephrology, Tunisia , Hdiji, Abdelhamid Sfax University Hospital - Department of Nephrology, Tunisia , Yaich, Somaya Sfax University Hospital - Department of Nephrology, Tunisia , Kharrat, Mahmoud Sfax University Hospital - Department of Nephrology, Tunisia , Charfeddine, Khaled Sfax University Hospital - Department of Nephrology, Tunisia , Hmida, Mohamed Ben Sfax University Hospital - Department of Nephrology, Tunisia , Mahfoudh, Hichem Sfax University Hospital - Department of Nephrology, Tunisia , Ayedi, Fatma Sfax University Hospital - Department of Biochemistry, Tunisia , Hachicha, Jamil Sfax University Hospital - Department of Nephrology, Tunisia
Abstract :
Regional citrate anticoagulation (RCA) was proposed by Pinnik et al as an alternative to heparin for intermittent hemodialysis (HD), [1] was first used by Morita et al. in 1961. [2] More recently, it is used for continuous hemodialysis [3] in high risk bleeding patients. Citrate achieves anticoagulation by forming complexes with ionized calcium. During HD, the citrate effect is most likely confined to the extra corporeal system because about 60% of the formed citrate complexes are removed from the blood by the dialyzer.
